Adlai Nortye Group Ltd. (ANL)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Adlai Nortye Reports $14.7M Working Capital Deficiency
# 🧾 What This Document Is This is Adlai Nortye's **annual report** (Form 20-F) for the year ended December 31, 2025. It's a comprehensive filing required by the U.S. SEC for foreign companies listed on American exchanges. Think of it as the company's official "year-in-review" and health check-up, p
Adlai Nortye Ltd. — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K**, a report that foreign companies listed on U.S. stock exchanges must file with the SEC. Think of it as a "here's what's new" update for investors. This specific filing from April 2026 is all about a significant **management change** at the company.
SEC filings
All filings →Insider trades
All insider trades →Adlai Nortye Group Ltd. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Adlai Nortye Group Ltd.
All people →No officers or directors have been indexed for Adlai Nortye Group Ltd..